Jounce seeking tumor-agnostic approach for ICOS agonist

Jounce said the ICOS hi CD4 T cells biomarker could allow the company to take a tumor-agnostic approach for its ICOS agonist vopratelimab (JTX-2011) to select patient populations more likely to respond to the therapy. Jounce Therapeutics Inc. (NASDAQ:JNCE) announced the news in its 4Q18 financial results Wednesday, then gained $1.06 (24%) to $5.45 on Thursday.

At the J.P. Morgan Healthcare Conference in January, President and CEO Richard Murray said that responses to vopratelimab were associated with emergence of the ICOS hi CD4 T cells biomarker...